Check out your Company Bowl for anonymous work chats.
Innoplexus featured in The Next Web (TNW)!! Read our CTO - Gaurav Tripathi's views on "How data is helping to upgrade #healthcare and #pharma innovation" http://glassdoor.com/slink.htm?key=vQ41N
Innoplexus featured in HuffPost!! Read our CTO - Gaurav Tripathi's views on how "Artificial Intelligence is shaping the future of Life Sciences and #Healthcare." http://glassdoor.com/slink.htm?key=vQ417
Here's our story : http://glassdoor.com/slink.htm?key=vQ41s - Dr. Gunjan Bhardwaj & Gaurav Tripathi
From Past Learning To Predictive Future" in Berlin on the 14th of July, 2017.
Two days to go for Machine Intelligence Summit! Our Founder & CEO, Dr. Gunjan Bhardwaj is participating in a panel discussion with cross-industry experts on "From Past Learning To Predictive Future" in Berlin on the 14th of July, 2017. Register here : http://mis.berlin/ Know More: http://glassdoor.com/slink.htm?key=vQ41U
Interventions based on tumor specific biomarkers are making development of precision medicine a reality. This infographic show-cases such interventions which are being developed in NSCLC based on the individual biomarker profile of a patient. Visit here : http://glassdoor.com/slink.htm?key=vQ41g
LAG-3 may be a better checkpoint inhibitor target than PD-1 and CTLA-4 since antibodies to these two checkpoints only activate effector T cells and do not inhibit Treg activity, whereas an antagonist LAG-3 antibody can do both. Boehringer Ingelheim, Bristol-Myers Squibb, Novartis. For more information read : http://glassdoor.com/slink.htm?key=vQ412
Migraine is a common neurovascular primary headache disorder with typical clinical features. In the Global Burden of Disease Study, migraine on its own was found to be the sixth highest cause worldwide of years lost due to disability. Amgen, Novartis, Eli Lilly For more information read : http://glassdoor.com/slink.htm?key=vQ41L
Join us to help build a million smiles across Life Science Industry.
Age-related macular degeneration (AMD) is a disease that causes gradual loss of sight due to blurring or loss of central vision in people over age of 60. It has impacted more than 20 million people worldwide. A new investigational drug, brolucizumab (or RTH258) by Novartis, may provide relief to these patients. For more informationn : http://glassdoor.com/slink.htm?key=vQ41D
